ORTHO-SUBSTITUTED BENZOIC ACID DERIVATIVES FOR THE TREATMENT OF INSULIN RESISTANCE

(19)

(11)

EP 1 517 883 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	21.05.2008 Bulletin 2008/21

(45)	Mention of the grant of the patent:
	13.02.2008 Bulletin 2008/07

(21)	Application number: 03732713.7

(22)	Date of filing: 17.06.2003

(51)

International Patent Classification (IPC):

C07C 235/34^(2006.01)
A61K 31/19^(2006.01)
A61P 3/10^(2006.01)

C07C 323/62^(2006.01)
A61P 3/06^(2006.01)

(86)	International application number:
	PCT/GB2003/002584

(87)	International publication number:
	WO 2004/000790 (31.12.2003 Gazette 2004/01)

(54)	ORTHO-SUBSTITUTED BENZOIC ACID DERIVATIVES FOR THE TREATMENT OF INSULIN RESISTANCE ORTHO-SUBSTITUIERTE BENZOESÄUREDERIVATE ZUR BEHANDLUNG VON INSULINRESISTENZ DERIVES DE L'ACIDE BENZOIQUE ORTHO-SUBSTITUES DESTINES AU TRAITEMENT DE L'INSULINORESISTANCE

(84)	Designated Contracting States:
	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR
	Designated Extension States:
	AL LT LV MK

(30)

Priority:

20.06.2002 SE 0201935
20.12.2002 SE 0203826

(43)	Date of publication of application:
	30.03.2005 Bulletin 2005/13

(73)	Proprietor: AstraZeneca AB
	151 85 Södertälje (SE)

(72)	Inventor:
	LI, Lanna S-431 83 Mölndal (SE)

(56)

References cited: :

EP-A- 0 802 186

EP-A- 1 184 366

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).